{"id":2164,"date":"2009-06-08T16:54:29","date_gmt":"2009-06-08T20:54:29","guid":{"rendered":"https:\/\/cqdm.org\/en\/news-and-events\/announcement-of-an-investment-of-close-to-8-million-dollars-in-biopharmaceutical-research-in-quebec\/"},"modified":"2024-09-25T16:41:06","modified_gmt":"2024-09-25T20:41:06","slug":"announcement-of-an-investment-of-close-to-8-million-dollars-in-biopharmaceutical-research-in-quebec","status":"publish","type":"post","link":"https:\/\/cqdm.org\/en\/news-and-events\/announcement-of-an-investment-of-close-to-8-million-dollars-in-biopharmaceutical-research-in-quebec\/","title":{"rendered":"Announcement of an investment of close to $8 million dollars in biopharmaceutical research in Qu\u00e9bec"},"content":{"rendered":"\n

The projects will have a major impact on the research and development of new drugs in the field of Alzheimer\u2019s disease, diabetes, cardiovascular diseases and vaccines<\/h2>\n\n\n\n

MONTR\u00c9AL, QC, June 8th, 2009. <\/p>\n\n\n\n

Four outstanding projects have been selected from the first competition on drug discovery launched by the CQDM in the fall of 2008. All research proposals have been evaluated through an exhaustive due diligence process involving, among others, an independent scientific and industrial expert panel led by the Fonds de recherche en sant\u00e9 du Qu\u00e9bec (FRSQ). These projects aimed at developing new enabling technologies that can significantly facilitate the drug discovery process. <\/p>\n\n\n\n

Quebec is recognized for the quality of its research. The selected CQDM\u2019s research projects will be conducted by multidisciplinary top level Quebec researchers, recognized as international leaders in their respective field.<\/p>\n\n\n\n

Because of its innovative and unique approach, CQDM promotes the creation of synergy between academic and industrial research. \u00abThe four awarded projects are perfectly wellaligned with CQDM\u2019s mission which is to fund innovative enabling tools andtechnologies that could have a significant impact on the drug discovery process for the biopharmaceutical industry\u00bb, said Max Fehlmann, President and CEO, CQDM. <\/p>\n\n\n\n

Based on genuine private-public partnerships, the selected projects involve four companies (Medicago, Caprion, SNC-Lavalin and Perkin Elmer) and four universities (McGill, Montreal, Laval and Sherbrooke). This investment will generate the 2 employment of more than 30 full time equivalent researchers, postdoctoral fellows and students.<\/p>\n\n\n\n

Thanks to the contributions and commitments of CQDM\u2019s private and public partners such as Pfizer Canada, AstraZeneca Canada, Merck Frosst Canada Ltd., the Fonds de la recherche en sant\u00e9 du Qu\u00e9bec (FRSQ), the Minist\u00e8re du D\u00e9veloppement \u00e9conomique, de l\u2019Innovation et de l\u2019Exportation (MDEIE) and the Business-Led Networks of Centres of Excellence (BL-NCE), it is possible to invest in cutting-edge technologies that could accelerate the development of more effective and safer drugs and consequently affect patient\u2019s health care.<\/p>\n\n\n\n

Further to fostering greater investments in R-D in the public sector and the biopharmaceutical industry, CQDM offers an original collaborative model from which new partnerships can emerge. \u201cThe number and the quality of the drug discovery proposals received for the first competition \u2013 78 – further underlines the dynamism of
research groups in the province of Quebec and demonstrate their willingness to collaborate with the industry to address the increasing medical challenges generated by the rising needs of an aging population\u201d, explains Bernard Prigent, Chairman of the Scientific Orientation Committee of CQDM and Medical Director of Pfizer Canada.<\/p>\n\n\n\n

This year CQDM\u2019s selected projects will focus on:<\/p>\n\n\n\n

    \n
  1. Developing a method to rapidly identify and test new vaccines against the influenza virus (for instance the A(H1N1) virus) and other families of viruses (Louis-Philippe V\u00e9zina, Medicago Inc.);<\/li>\n\n\n\n
  2. Developing tools to allow the early identification of patients with Alzheimer\u2019s disease (Louis Collins, Montreal Neurological Institute, McGill University);<\/li>\n\n\n\n
  3. Discovering and validating new biomarkers to better monitor the progression of diabetes and the response to treatments (Eustache Paramithiotis, Caprion Proteomics Inc.);<\/li>\n\n\n\n
  4. Developing molecular and cellular tools to predict efficacy of new drugs (Michel Bouvier, IRIC, Universit\u00e9 de Montr\u00e9al).<\/li>\n<\/ol>\n\n\n\n

    The presentation and announcement of the projects will be made on June 8th, 2009 during the CQDM\/Montreal InVivo Creative Partnerships in Biopharmaceutical Research Forum. \u00ab This event will allow the partners from the public and private biopharmaceutical sector and other stakeholders of the industry to share their views on
    critical issues for Quebec, such as the productivity and value-added creation of the research conducted\u201d, indicated Michelle Savoie, Montr\u00e9al InVivo\u2019s CEO. <\/p>\n\n\n\n

    The event will be held at the Club Saint-James in Montr\u00e9al.<\/p>\n\n\n\n

    About CQDM<\/h3>\n\n\n\n

    CQDM is a not-for-profit organization that responds to the needs of the pharmaceutical industry by contributing to accelerating drug discovery and developing safer, more effective drugs. CQDM\u2019s funding is provided by the FRSQ, the MDEIE, the BL-NCE, Pfizer Canada, AstraZeneca Canada and Merck Frosst Canada Ltd.<\/p>\n\n\n\n

    For more information, visit:<\/em> www.cqdm.org<\/p>\n\n\n\n

    Source:
    Christine O\u2019Doherty
    Montr\u00e9al InVivo (514) 987.9378
    christine.odoherty@montreal-invivo.com<\/p>\n\n\n\n

    Fact sheets and researchers bios are available at the following address: http:\/\/creativepartnerships2009.montreal-invivo.com\/<\/p>\n\n\n\n

    \n
    PDF article<\/a><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    The projects will have a major impact on the research and development of new drugs in the field of Alzheimer\u2019s disease, diabetes, cardiovascular diseases and vaccines MONTR\u00c9AL, QC, June 8th, 2009. Four outstanding projects have been selected from the first competition on drug discovery launched by the CQDM in the fall of 2008. All research…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2164","post","type-post","status-publish","format-standard","hentry","category-our-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/2164","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/comments?post=2164"}],"version-history":[{"count":4,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/2164\/revisions"}],"predecessor-version":[{"id":4115,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/posts\/2164\/revisions\/4115"}],"wp:attachment":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media?parent=2164"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/categories?post=2164"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/tags?post=2164"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}